U.S. stocks closed about 1 percent lower as investors eyed renewed strength in the dollar and data that could strengthen the case for a rate hike.» Read More
Michael Yoshikami is rounding out the week with an eye toward quality. The president and chief investment strategist of YCMNET Advisors picks two Dow Jones industrials as his Friday trades.
Warren Buffett's Berkshire Hathaway has added a new stake in NRG Energy, according to a just-released portfolio 'snapshot' of its holdings in U.S. publicly-traded stocks as of June 30. A sharply reduced stake in Anheuser-Busch may have been a bet that InBev's initially unsolicited offer for the U.S. brewer would prove to be unsuccessful. Conoco-Phillips data is kept "confidential."
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
For investors there really is no place like home. Find out why!
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
David Pearl of Epoch Investment Partners and David Moon of Moon Capital Management offered CNBC their insights. (Part 2: Personal Products)
Here's the Thursday edition of the Fast Money Final Trade. The crew presents tomorrow's best trades, right now!
The pitter-patter of little feet and the high-pitched cries of infants may seem louder lately, but it's music to the ears of many companies that cater to infants and children.
Stocks advanced Tuesday, building on the prior session's rally, as a drop in oil prices and encouraging outlook from Cisco helped offset disappointment in Freddie Mac's results.
With the Olympics about to begin, some multinationals are betting big with over $800 million in sponsorship rights. Does the big investment in advertising payoff?
Here's our Fast Money Final Trade. Tomorrow's best trades, right now!
Health care stocks have been the stealth performers, and they will likely continue to outperform because of steady earnings, a favorable macro environment and cheap valuations, says Merrill Lynch's Brian Belski.
Cramer makes the call on viewers' favorite stocks.
Mat DiFilippo, senior portfolio manager at Stewart Capital and Randy Lert, chief portfolio strategist at Russell Investments offered advice on different sectors that could help benefit investors.
Bruce Levis, managing director at McQueen, Ball & Associates, says that the market has yet to hit bottom, but offered a few sector selections that could benefit investors.
So Exxon Mobil has just broken its own record again, reporting a mind-boggling $11.6 billion profit on $138 billion in sales. Windfall? Nope: Microsoft is three times more profitable than Exxon.
The Dow tumbled on Monday as more credit and housing market turmoil battered financial shares.
In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.